Cancer Family
Intestinal Neoplasm
CI-CAN-00000209Explore in graph →
Non-malignant1,893 active trials21 approved drugs383 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000209Explore in graph →
Clinical trials
9,158 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04767984 | Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis | active not recruiting | Phase 2 | 42 | Northwestern UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07286695 | Fruquintinib Combined With Trifluridine/Tipiracil Versus Bevacizumab Combined With Trifluridine/Tipiracil for Advanced Metastatic Colorectal Cancer | not yet recruiting | Phase 2 | 292 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 21, 2026 |
| clinicaltrials |
| NCT00826540 | Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer | completed | Phase 2 | 83 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT06006923 | Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer | terminated | Phase 2 | 1 | Anwaar SaeedOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT07353268 | Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety, Tolerability, and Efficacy. | not yet recruiting | Phase 2 | 76 | Tao ZhangOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT02584244 | Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers | recruiting | Phase 1 / Phase 2 | 66 | Lumicell, Inc.INDUSTRY | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07347951 | A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer | recruiting | Phase 2 | 30 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT00335816 | Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer | active not recruiting | Phase 2 | 248 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Jan 14, 2026 | clinicaltrials |
| NCT03228667 | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | active not recruiting | Phase 2 | 40 | ImmunityBio, Inc.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT04744831 | Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer(DESTINY-CRC02) | completed | Phase 2 | 122 | Daiichi SankyoINDUSTRY | 10 | Jan 14, 2026 | clinicaltrials |
| NCT06864013 | SCRT Combined With Chemotherapy and Iparomlimab and Tuvonralimab in MSS or pMMR Patients With Locally Advanced Rectal Cancer | recruiting | Phase 2 | 116 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT05002270 | JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation | completed | Phase 1 / Phase 2 | 29 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT05651022 | Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 120 | Indaptus Therapeutics, IncINDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT06312982 | A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer | recruiting | Phase 2 / Phase 3 | 375 | Beijing Friendship HospitalOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT07337551 | Gossypol Acetate + FOLFIRI + Bev in mCRC With TP53-Mutant and LRPPRC Positive | not yet recruiting | Phase 2 | 20 | Guiying WangOTHER | 0 | Jan 13, 2026 | clinicaltrials |
| NCT04689347 | 5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer. | recruiting | Phase 1 / Phase 2 | 27 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT05504252 | METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin(METIMMOX-2) | active not recruiting | Phase 2 | 80 | University Hospital, AkershusOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT07321847 | Injection of IP-001 Into Thermally Ablated Hepatic Tumors in Patients With Colorectal Liver Metastases(INJECTABL-3) | not yet recruiting | Phase 2 / Phase 3 | 717 | Immunophotonics, Inc.INDUSTRY | 0 | Jan 7, 2026 | clinicaltrials |
| NCT05296681 | Microbiotic Product to Promote Microbiome Health and Improve Chemotherapy Delivery | recruiting | Phase 2 | 42 | Howard S. Hochster, MDOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07068763 | Node-Sparing Short-Course Radiation Combined With Capecitabine and PD-1/CTLA-4 for MSS Early Rectal Cancer(mRCAT-E) | recruiting | Phase 2 | 52 | Sir Run Run Shaw HospitalOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT03921684 | Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients | active not recruiting | Phase 2 | 29 | Baruch BrennerOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT03983993 | Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer(NIPAVect) | active not recruiting | Phase 2 | 26 | Emory UniversityOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT04556253 | AK104 in Locally Advanced MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer | active not recruiting | Phase 2 | 47 | Peking UniversityOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT05215379 | Neoadjuvant Chemoradiation Therapy Combined With Immunotherapy for MSS Ultra-low Rectal Cancer | completed | Phase 2 / Phase 3 | 201 | Changhai HospitalOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT07314528 | Evaluating the Impact of GLP-1 Receptor Agonists With Total Neoadjuvant Therapy in Rectal Cancer | not yet recruiting | Phase 2 | 42 | St. James's Hospital, IrelandOTHER | 0 | Jan 2, 2026 | clinicaltrials |
| NCT03844750 | Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases | terminated | Phase 2 | 6 | Chloe Atreya, MD, PhDOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT04141449 | A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation(Potlako+) | active not recruiting | Phase 2 | 874 | Brigham and Women's HospitalOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT07279077 | Node-Sparing Low-Dose Radiotherapy Concurrent With Chemotherapy and PD-1 Inhibitor in pMMR/MSS High-Risk Locally Advanced Colon Cancer: A Prospective, Single-Arm, Phase II Trial(MODIFI-L) | recruiting | Phase 2 | 38 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT06640283 | Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical Outcomes(ANA) | recruiting | Phase 2 | 150 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT06722183 | Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities(FUTURE) | recruiting | Phase 2 | 33 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT06934538 | First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer | recruiting | Phase 1 / Phase 2 | 90 | Brenus PharmaINDUSTRY | 3 | Dec 22, 2025 | clinicaltrials |
| NCT07297030 | SIB-RT Combined With CAPOX and PD-1 for High-Risk Rectal Cancer | not yet recruiting | Phase 2 | 37 | Sun Yat-sen UniversityOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT07192068 | Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.(AcSé HER2) | recruiting | Phase 2 | 105 | UNICANCEROTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT05902533 | REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation(REDEL) | active not recruiting | Phase 2 / Phase 3 | 33 | University of CincinnatiOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05472948 | Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma | recruiting | Phase 2 | 36 | Sun Yat-sen UniversityOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT05959356 | Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer(CEIL) | recruiting | Phase 2 | 198 | Sun Yat-sen UniversityOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT06714357 | ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer(VICTORIA) | recruiting | Phase 2 | 130 | National Cancer Institute, NaplesOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT07213570 | STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer | recruiting | Phase 2 | 60 | National Cancer Institute, NaplesOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT07284992 | SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC | recruiting | Phase 2 | 208 | Shandong Provincial HospitalOTHER_GOV | 1 | Dec 16, 2025 | clinicaltrials |
| NCT06856837 | - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases | recruiting | Phase 2 | 140 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 2 | Dec 12, 2025 | clinicaltrials |
| NCT04417699 | SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer(SHORT) | completed | Phase 2 | 13 | Providence Health & ServicesOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT05289830 | Escitalopram to Placebo in Patients With Localized Pancreatic Cancer | terminated | Phase 2 | 4 | Case Comprehensive Cancer CenterOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT06245356 | Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer(TRIFLUOX-DP) | recruiting | Phase 2 | 73 | UNICANCEROTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT05131919 | Pembrolizumab for Locally Advanced, Irresectable, Non-metastatic dMMR Colorectal Cancers(PUMA) | active not recruiting | Phase 2 | 25 | The Netherlands Cancer InstituteOTHER | 1 | Dec 9, 2025 | clinicaltrials |
| NCT07272772 | Colon Cancer Diagnosis With FAPI-PET Imaging | recruiting | Phase 2 / Phase 3 | 100 | Turku University HospitalOTHER_GOV | 1 | Dec 9, 2025 | clinicaltrials |
| NCT07268677 | A Single-arm Clinical Study Evaluating Pirfenidone and Sintilimab in Combination With Standard Neoadjuvant Chemotherapy for Colorectal Cancer Patients With Peritoneal Metastasis. | not yet recruiting | Phase 2 | 30 | Guoxiang CaiOTHER | 0 | Dec 8, 2025 | clinicaltrials |
| NCT02437071 | Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients | completed | Phase 2 | 34 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT06731894 | Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors | recruiting | Phase 2 | 120 | City of Hope Medical CenterOTHER | 1 | Dec 5, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jan 21, 2026source: clinicaltrials